CA-TIGO
6.4.2022 16:02:05 CEST | Business Wire | Press release
Tigo Energy, Inc. , the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, today revealed that one of the Company’s solar systems in the Netherlands consistently produces 30% more energy by using Tigo MLPE Optimizers. The drastic increase in energy production was measured on a per-module basis by the Tigo EI software using the exclusive Reclaimed Energy feature. Solar installers planning to attend Solar Solutions International 2022 in Vijfhuizen are invited to meet with Tigo representatives to discuss hardware and software solutions like those used in this installation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005028/en/
The 12kWp solar system was designed and installed by homeowner Hans de Git, an energy consultant at NL HDG Energie Advies. The array spans five different roof orientations on the residence in North Holland and combines Tigo TS4-A-O optimizers with a Cloud Connect Advanced (CCA) datalogger and Tigo Access Point (TAP) antennas to enable rapid shutdown, module-level visibility, and Reclaimed Energy optimization. This universal system architecture is powered by Tigo EI software and eliminates the complications of mismatches caused by varied module orientations as well as variations in module output and inverter characteristics. Over the last two years, the system has generated 5MWh of clean energy, of which 1.5MWh represented reclaimed energy provided by the Tigo TS4-A-O optimizers.
“We started using Tigo in 2012, and we have become great fans of the Tigo family of solar MLPE optimizers because they bring benefits to us as the installer and our customers,” said Mr. de Git. “When it came time to choose equipment for a new PV installation on my own house, I didn’t hesitate to choose Tigo again. Because of the specific layout of the array, I would have needed at least five MPPTs to make it work properly, which would have meant adding at least one more inverter. With the Tigo TS4 platform, I avoided the expense of additional inverters, and I can now fully exploit the double MPP tracker of my string inverter.”
“Hearing about the success of Mr. de Git is what the solar industry is all about for me,” said Jaap van Kriekingen, business development manager for Benelux at Tigo Energy. “Tigo EI software provides a clear visual readout of energy production for homeowners, allowing them to see the benefits brought by optimization over time. This level of down-to-the-hour visualization provides the peace of mind that their PV systems are performing at their very best.”
Both Jaap van Kriekingen and Mirko Bindi, Tigo VP EMEA Sales and MD Europe, respectively, will be present at the Solar Solutions International at Expo Haarlemmermeer in Vijfhuizen, the Netherlands, from April 12-14, 2022 at IBC Solar B.V. booth nr B11.1. IBC Solar, which produces tailor-made solutions ranging from small residential PV plants to major solar projects in the Benelux region, will introduce its new AeroFix G3 mounting system at the expo.
To learn more about the Tigo TS4 platform and its exclusive Reclaimed Energy feature, read the latest case study or visit www.tigoenergy.com/ts4 .
About Tigo Energy
Tigo Energy, the worldwide leader in Flex MLPE (Module Level Power Electronics), designs innovative solar power conversion and storage products that provide customers more choice and flexibility. The Tigo TS4 platform increases solar production, decreases operating costs, and enhances safety. When combined with the Tigo Energy Intelligence (EI) platform, it delivers module, system, and fleet-level insights to maximize solar performance and minimize operating costs. The Tigo EI Residential Solar Solution , a flexible solar-plus-storage solution for home installations, rounds out the Company’s portfolio of solar energy technology. Tigo was founded in Silicon Valley in 2007 to accelerate the adoption of solar energy, and its global team supports customers whose systems reliably produce gigawatt-hours of safe solar energy on seven continents. Find us online at www.tigoenergy.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom